Putative Pathogenic Variants of ABCG5 and ABCG8 of Sitosterolemia in Patients With Hyper-Low-Density Lipoprotein Cholesterolemia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveSitosterolemia is a rare autosomal recessive disease caused by the deleterious variants of adenosine 5'-triphosphate (ATP)-binding cassette sub-family G member 5 (ABCG5) or ATP-binding cassette sub-family G member 8 (ABCG8). There are only few data on the pathogenicity of ABCG5 and ABCG8. This study aimed to propose a scheme for determining variant pathogenicity and to catalog the putative pathogenic variants in sitosterolemia. MethodsThis study enrolled 377 consecutive Japanese patients with hyper-low-density lipoprotein cholesterolemia (mean age: 46.5±19.8 years, with 192 men) who have targeted-sequenced data on ABCG5 or ABCG8 (among 21 Mendelian lipid genes for any dyslipidemias) and serum sitosterol levels at Kanazawa University Hospital from 2016 to 2021. Serum sitosterol levels were divided by 0.79 in patients treated with ezetimibe, accounting for the average reduction with this drug. ABCG5 or ABCG8 variants were defined as putative pathogenic if associated with serum sitosterol levels ≥5 µg/mL or homozygous if associated with serum sitosterol levels ≥10 µg/mL. ResultsTwenty-three ABCG5 or ABCG8 variants (16 missense, 2 nonsense, 2 frameshift, 2 deletion, and 1 splice mutation) were identified. Based on our definition, 11 putative pathogenic variants (median sitosterol level: 10.1 [6.5–17.1] µg/mL) were found in 36 individuals and 12 benign variants (median sitosterol: 3.5 [2.5–4.1] µg/mL) in 14 individuals. ConclusionThe scheme proposed for assessing the pathogenicity of genetic variations (ABCG5 and ABCG8) is useful. Using this scheme, 11 putative pathogenic, and 12 benign variants in ABCG5 or ABCG were classified.
Abstract
ObjectiveSitosterolemia is a rare autosomal recessive disease caused by the deleterious variants of adenosine 5'-triphosphate (ATP)-binding cassette sub-family G member 5 (ABCG5) or ATP-binding cassette sub-family G member 8 (ABCG8). There are only few data on the pathogenicity of ABCG5 and ABCG8. This study aimed to propose a scheme for determining variant pathogenicity and to catalog the putative pathogenic variants in sitosterolemia. MethodsThis study enrolled 377 consecutive Japanese patients with hyper-low-density lipoprotein cholesterolemia (mean age: 46.5±19.8 years, with 192 men) who have targeted-sequenced data on ABCG5 or ABCG8 (among 21 Mendelian lipid genes for any dyslipidemias) and serum sitosterol levels at Kanazawa University Hospital from 2016 to 2021. Serum sitosterol levels were divided by 0.79 in patients treated with ezetimibe, accounting for the average reduction with this drug. ABCG5 or ABCG8 variants were defined as putative pathogenic if associated with serum sitosterol levels ≥5 µg/mL or homozygous if associated with serum sitosterol levels ≥10 µg/mL. ResultsTwenty-three ABCG5 or ABCG8 variants (16 missense, 2 nonsense, 2 frameshift, 2 deletion, and 1 splice mutation) were identified. Based on our definition, 11 putative pathogenic variants (median sitosterol level: 10.1 [6.5–17.1] µg/mL) were found in 36 individuals and 12 benign variants (median sitosterol: 3.5 [2.5–4.1] µg/mL) in 14 individuals. ConclusionThe scheme proposed for assessing the pathogenicity of genetic variations (ABCG5 and ABCG8) is useful. Using this scheme, 11 putative pathogenic, and 12 benign variants in ABCG5 or ABCG were classified.
참고문헌 (19)
- Escolà-Gil JC, "Sitosterolemia : diagnosis, investigation, and management", Curr Atheroscler Rep, 16, pp.424~ (2014)
- Salen G, "Sitosterolemia", J Lipid Res, 33, pp.945~955 (1992)
- Tada H, "Diagnosis and management of sitosterolemia 2021", J Atheroscler Thromb, 28, pp.791~801 (2021)
- Yoshida H, "Reference intervals of serum non-cholesterol sterols by gender in healthy Japanese individuals", J Atheroscler Thromb, 27, pp.409~417 (2020)
- Gok V, "A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia", Clin Chim Acta, 529, pp.61~66 (2022)
- Tada H, "Rare and deleterious mutations in ABCG5", ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype, 2019, pp.83, 1917~1924
- Tanaka H, "Sitosterolemia exhibiting severe hypercholesterolemia with tendon xanthomas due to compound heterozygous ABCG5 gene mutations treated with ezetimibe and alirocumab", Intern Med, 59, pp.3033~3037 (2020)
- Tada H, "Children with severe hypercholesterolemia caused by a pathogenic mutation in ABCG5", Intern Med, 62, pp.251~259 (2023)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Kojima N, "Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations", Clin Chim Acta, 507, pp.11~16 (2020)
- Tada H, "Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease", J Clin Lipidol, 12, pp.1436~1444 (2018)
- Salen G, "Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia", Circulation, 109, pp.966~971 (2004)
- Karczewski KJ, "The mutational constraint spectrum quantified from variation in 141, 456 humans", Nature, 581, pp.434~443 (2020)
- Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, "Report of the committee on the classification and diagnostic criteria of diabetes mellitus", J Diabetes Investig, 1, pp.212~228 (2010)
- Nohara A, "Homozygous familial hypercholesterolemia", J Atheroscler Thromb, 28, pp.665~678 (2021)
- Nomura A, "Heterozygous ABCG5 gene deficiency and risk of coronary artery disease", Circ Genom Precis Med, 13, pp.417~423 (2020)
- Tada H, "Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene", Lipids Health Dis, 19, pp.3~ (2020)
- Tada H, "Challenges of precision medicine for atherosclerotic cardiovascular disease based on human genome information", J Atheroscler Thromb, 28, pp.305~313 (2021)
- Dayspring TD, "Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667, 718 patients", J Clin Lipidol, 9, pp.807~816 (2015)